Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Morgan

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 23, 2016
Salient Features of Endonuclease Platforms for Therapeutic Genome EditingMichael T Certo, Richard A Morgan
AIDS Patient Care and Stds|February 13, 2002
Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genesMario R Mautino, Richard A Morgan
Human Gene Therapy|June 18, 2002
Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNAMario R Mautino, Richard A Morgan
The Journal of Gene Medicine|May 22, 2012
Cancer therapy with genetically-modified T cells for the treatment of melanomaKiran H Lagisetty, Richard A Morgan
Journal of Translational Medicine|February 15, 2012
Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometryZhili Zheng, Nachimuthu Chinnasamy, Richard A Morgan
The Journal of Surgical Research|April 16, 2013
Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinaseCary Hsu, John D Abad, Richard A Morgan
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 4, 2008
Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cellsShicheng Yang, Steven A Rosenberg, Richard A Morgan
Trends in Biotechnology|June 14, 2011
Treating cancer with genetically engineered T cellsTristen S Park, Steven A Rosenberg, Richard A Morgan
Oncoimmunology|August 2, 2014
Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapiesDaniel Abate-Daga, Steven A Rosenberg, Richard A Morgan
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Adoptive cell therapy: genetic modification to redirect effector cell specificityRichard A Morgan, Mark E Dudley, Steven A Rosenberg
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 23, 2016
Salient Features of Endonuclease Platforms for Therapeutic Genome EditingMichael T Certo, Richard A Morgan
AIDS Patient Care and Stds|February 13, 2002
Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genesMario R Mautino, Richard A Morgan
Human Gene Therapy|June 18, 2002
Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNAMario R Mautino, Richard A Morgan
The Journal of Gene Medicine|May 22, 2012
Cancer therapy with genetically-modified T cells for the treatment of melanomaKiran H Lagisetty, Richard A Morgan
Journal of Translational Medicine|February 15, 2012
Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometryZhili Zheng, Nachimuthu Chinnasamy, Richard A Morgan
The Journal of Surgical Research|April 16, 2013
Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinaseCary Hsu, John D Abad, Richard A Morgan
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 4, 2008
Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cellsShicheng Yang, Steven A Rosenberg, Richard A Morgan
Trends in Biotechnology|June 14, 2011
Treating cancer with genetically engineered T cellsTristen S Park, Steven A Rosenberg, Richard A Morgan
Oncoimmunology|August 2, 2014
Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapiesDaniel Abate-Daga, Steven A Rosenberg, Richard A Morgan
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Adoptive cell therapy: genetic modification to redirect effector cell specificityRichard A Morgan, Mark E Dudley, Steven A Rosenberg
Pageof 13